Here’s what keeps pharma leaders awake at night: 70% to 80% of ChatGPT usage is healthcare-related/ However, most pharmaceutical organizations still treat AI as a future consideration rather than an immediate competitive necessity.
In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Emily Lewis, Artificial Intelligence and Innovation Lead for Digital Care Transformation at UCB, to explore why LLMs alone won’t move medicine forward, how to build cross-functional AI literacy across your organization, and the regulatory workflows where AI will deliver impact fastest.
What You’ll Learn:
  • Why LLMs alone aren’t enough for medicine
  • How to stop waiting for corporate training and start building AI competency yourself
  • Why the regulatory space is the fastest, lowest-hanging fruit for AI impact
  • How to stay ahead while managing information overload
  • Why consumerization in pharma is about patient empowerment
Emily Lewis is the Artificial Intelligence and Innovation Lead for Digital Care Transformation at UCB. With nearly two decades of experience across clinical operations, digital health, patient engagement, and AI strategy, Emily has built a career helping organizations rethink how data, machine learning, and human-centered design can transform patient care. Emily is also a global educator, advisor, and advocate,  teaching AI in pharma, advising on ethical AI, mentoring future innovators, and contributing to thought leadership across organizations like Harvard Business Review, HITLAB, and Women Techmakers.

Disclaimer: Pharma Sessions is for informational purposes only and does not constitute medical, legal, or financial advice. Guest opinions are their own and do not reflect the views of the host or sponsors. Use of any information provided is at the listener’s own risk and does not imply endorsement of specific products or strategies.

Episode Resources:
Or join the Pharma Sessions Substack:
www.pharmasessions.substack.com
Pharma Sessions is handcrafted by our friends over at: fame.so